Form 8-K - Current report:
SEC Accession No. 0000950170-25-020465
Filing Date
2025-02-14
Accepted
2025-02-14 08:50:50
Documents
13
Period of Report
2025-02-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K apvo-20250214.htm   iXBRL 8-K 43537
2 EX-99.1 apvo-ex99_1.htm EX-99.1 207181
3 GRAPHIC img237228349_0.jpg GRAPHIC 14823
  Complete submission text file 0000950170-25-020465.txt   405533

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apvo-20250214.xsd EX-101.SCH 26037
15 EXTRACTED XBRL INSTANCE DOCUMENT apvo-20250214_htm.xml XML 4925
Mailing Address 2401 4TH AVE. SUITE 1050 SEATTLE WA 98121
Business Address 2401 4TH AVE. SUITE 1050 SEATTLE WA 98121 206-838-0500
Aptevo Therapeutics Inc. (Filer) CIK: 0001671584 (see all company filings)

EIN.: 811567056 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37746 | Film No.: 25623581
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)